- Home
- MPB vs PHAR Comparison
MPB vs PHAR Comparison
Compare MPB & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- PHAR
- Stock Information
- Founded
- MPB 1868
- PHAR 1988
- Country
- MPB United States
- PHAR Netherlands
- Employees
- MPB N/A
- PHAR N/A
- Industry
- MPB Major Banks
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- PHAR Health Care
- Exchange
- MPB Nasdaq
- PHAR Nasdaq
- Market Cap
- MPB 525.0M
- PHAR 618.3M
- IPO Year
- MPB N/A
- PHAR N/A
- Fundamental
- Price
- MPB $29.19
- PHAR $8.20
- Analyst Decision
- MPB Buy
- PHAR Strong Buy
- Analyst Count
- MPB 2
- PHAR 3
- Target Price
- MPB $36.00
- PHAR $27.00
- AVG Volume (30 Days)
- MPB 71.0K
- PHAR 5.6K
- Earning Date
- MPB 01-22-2025
- PHAR 03-13-2025
- Dividend Yield
- MPB 2.74%
- PHAR N/A
- EPS Growth
- MPB 14.41
- PHAR N/A
- EPS
- MPB 2.91
- PHAR N/A
- Revenue
- MPB $173,416,000.00
- PHAR $285,745,000.00
- Revenue This Year
- MPB N/A
- PHAR $20.08
- Revenue Next Year
- MPB $19.26
- PHAR $9.22
- P/E Ratio
- MPB $10.05
- PHAR N/A
- Revenue Growth
- MPB 4.93
- PHAR 30.64
- 52 Week Low
- MPB $19.20
- PHAR $6.65
- 52 Week High
- MPB $33.87
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- MPB 46.67
- PHAR 36.29
- Support Level
- MPB $30.02
- PHAR $8.49
- Resistance Level
- MPB $31.36
- PHAR $9.35
- Average True Range (ATR)
- MPB 0.75
- PHAR 0.55
- MACD
- MPB 0.16
- PHAR -0.17
- Stochastic Oscillator
- MPB 45.23
- PHAR 12.14
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.